Press Release Archive
Press Releases
February 2019
02.16.2019 Research Pivotal Phase III Data for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) in Advanced Renal Cell Carcinoma Published in The New England Journal of Medicine 02.12.2019 Partnerships G-CON Manufacturing Delivers New PCMM POD® With Tablet Coating Capability to Pfizer Inc.’s Groton, Conn. Site 02.11.2019 Medicines FDA Accepts sBLA and Grants Priority Review for BAVENCIO® (avelumab) Plus INLYTA® (axitinib) for the Treatment of Advanced Renal Cell Carcinoma 02.11.2019 Research Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer 02.04.2019 Responsibility The Union For International Cancer Control And Pfizer Announce New Phase Of Global Grants Initiative Supporting Metastatic Breast Cancer Patients 02.01.2019 Medicines Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
January 2019
01.29.2019 Finance PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2018 RESULTS 01.29.2019 Research Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain 01.14.2019 Medicines US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy 01.09.2019 Partnerships eFFECTOR Enters Into Agreement with Pfizer Inc. to Develop Novel First-inClass Inhibitors of eIF4E to Treat Multiple Cancer Types 01.07.2019 Partnerships CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason’s Machine Learning Model of the Immune System for Drug Discovery 01.03.2019 Research Pfizer Initiates Phase 2b/3 Clinical Trial for PF-06651600, an Oral JAK3 Inhibitor, for the Treatment of Patients with Moderate to Severe Alopecia Areata
Media Resources & Contact Information
Anyone may view our press releases, press statements, and press kits.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.